Introduction
Methods
Results
IM400 | IM800 |
p value, IM400/IM800 combined | ||||
---|---|---|---|---|---|---|
Age (years), (n) | <65 (272) | ≥65 (110) | <65 (319) | ≥65 (83) | <65 vs. ≥65 | |
Age (years), median (range) | 48 (16–64) | 70 (65–88) | 46 (18–64) | 69 (65–85) | – | |
Sex female (%) | 38 | 45 | 41 | 41 | ns | |
Karnofsky index (%) | 0–85 | 11 | 16 | 10 | 18 | 0.03 |
90–95 | 31 | 38 | 31 | 30 | 0.03 | |
100 | 58 | 46 | 59 | 52 | 0.03 | |
Hemoglobin (g/dl), median (range) | 12.1 (4.9–17.5) | 12.8 (6.4–16.2) | 12.1 (4.7–19.1) | 12.4 (6.5–15.7) | <0.01 | |
White blood cell count ×109/l, median (range) | 81.6 (5.7–574) | 58.0 (6.6–582) | 93.8 (2.6–554) | 43.8 (5.1–570) | <0.01 | |
Platelets ×109/l, median (range) | 373 (89–2,419) | 390 (58–2,337) | 388 (39–2,582) | 400 (88–2,716) | ns | |
Spleen size (cm below costal margin), median (range) | 2 (0–28) | 0 (0–16) | 2 (0–30) | 0 (0–23) | <0.01 | |
EURO score (%) | Low | 45 | 11 | 45 | 12 | nda
|
Intermediate | 42 | 77 | 42 | 72 | nda
| |
High | 13 | 12 | 13 | 16 | nda
| |
EUTOS score (%) | Low | 87 | 91 | 85 | 86 | ns |
High | 13 | 9 | 15 | 14 | ns |
IM400 | IM800 | ||||
---|---|---|---|---|---|
Age (years) | <65 | ≥65 | <65 | ≥65 | |
Months | Doses | ||||
Median (mg/day) | |||||
0–3 | 400 | 400 | 563 | 472 | |
3–6 | 400 | 400 | 773 | 494 | |
6–9 | 400 | 400 | 629 | 400 | |
9–12 | 400 | 400 | 600 | 400 | |
12–15 | 400 | 400 | 600 | 400 | |
15–18 | 400 | 400 | 600 | 400 | |
18–21 | 400 | 400 | 600 | 400 | |
21–24 | 400 | 400 | 600 | 400 | |
<390 mg/day (%) | |||||
0–3 | 3.5 | 4.9 | 1.3 | 0.0 | |
3–6 | 6.4 | 4.0 | 4.3 | 2.6 | |
6–9 | 5.8 | 3.2 | 3.6 | 0.0 | |
9–12 | 4.9 | 3.4 | 2.2 | 0.0 | |
12–15 | 3.4 | 4.7 | 2.0 | 1.5 | |
15–18 | 3.2 | 3.7 | 1.3 | 1.6 | |
18–21 | 2.8 | 3.8 | 2.2 | 0.0 | |
21–24 | 2.5 | 4.0 | 2.4 | 0.0 | |
390–410 mg/day (%) | |||||
0–3 | 94.6 | 94.1 | 21.8 | 39.0 | |
3–6 | 91.0 | 95.0 | 20.8 | 36.8 | |
6–9 | 89.2 | 95.7 | 32.2 | 58.0 | |
9–12 | 87.7 | 94.3 | 41.1 | 62.1 | |
12–15 | 89.0 | 92.9 | 41.7 | 69.1 | |
15–18 | 87.8 | 87.7 | 43.0 | 68.9 | |
18–21 | 88.2 | 88.8 | 41.6 | 70.7 | |
21–24 | 86.4 | 86.7 | 44.5 | 71.7 | |
>410–599 mg/day (%) | |||||
0–3 | 1.5 | 0.9 | 41.6 | 36.6 | |
3–6 | 1.1 | 0.0 | 11.6 | 23.7 | |
6–9 | 3.1 | 1.1 | 9.2 | 8.7 | |
9–12 | 4.5 | 2.3 | 4.5 | 12.1 | |
12–15 | 3.8 | 0.0 | 4.0 | 3.4 | |
15–18 | 2.7 | 6.2 | 3.4 | 3.3 | |
18–21 | 2.4 | 3.8 | 3.1 | 3.5 | |
21–24 | 4.0 | 2.7 | 1.0 | 3.8 | |
600–790 mg/day (%) | |||||
0–3 | 0.4 | 0.0 | 14.5 | 8.5 | |
3–6 | 0.8 | 0.0 | 12.9 | 18.4 | |
6–9 | 1.5 | 0.0 | 7.1 | 15.9 | |
9–12 | 2.1 | 0.0 | 3.4 | 10.6 | |
12–15 | 0.0 | 2.4 | 4.4 | 8.8 | |
15–18 | 4.1 | 0.0 | 9.8 | 6.6 | |
18–21 | 4.2 | 0.0 | 9.7 | 8.6 | |
21–24 | 4.0 | 0.0 | 8.1 | 9.4 | |
>790–800 mg/day (%) | |||||
0–3 | 0.0 | 0.0 | 18.8 | 15.9 | |
3–6 | 0.8 | 1.0 | 47.5 | 18.4 | |
6–9 | 0.4 | 0.0 | 44.3 | 17.4 | |
9–12 | 0.8 | 0.0 | 44.8 | 15.2 | |
12–15 | 0.0 | 0.0 | 41.7 | 16.2 | |
15–18 | 2.3 | 1.2 | 42.6 | 19.7 | |
18–21 | 2.4 | 3.8 | 42.9 | 17.2 | |
21–24 | 3.0 | 4.0 | 43.5 | 0.0 |
IM400 | IM800 | |||
---|---|---|---|---|
Age (years), (n) | <65 (254a) | ≥65 (96a) | <65 (288a) | ≥65 (73a) |
Adverse events | ||||
WHO grades 1–4 (%) | ||||
Anemiab
| 51.4 | 61.4 | 53.1 | 54.9 |
Leukocytopeniac
| 56.7 | 58.3 | 64.7 | 48.0 |
Thrombocytopeniad
| 36.9 | 34.5 | 35.6 | 32.9 |
Myalgia/arthralgiae
| 19.0 | 11.7 | 28.9 | 20.8 |
Dermatologic AEse
| 12.6 | 14.9 | 27.5 | 33.3 |
Edemae
| 24.9 | 24.5 | 40.1 | 45.8 |
Gastrointestinal AEse
| 26.1 | 23.4 | 48.2 | 47.2 |
Neurological AEse
| 15.4 | 6.4 | 16.9 | 20.8 |
Infectione
| 6.3 | 4.3 | 12.0 | 15.3 |
Fatiguee
| 14.2 | 8.5 | 19.7 | 15.3 |
Allergy/immunologye
| 1.2 | 4.3 | 2.5 | 0 |
Constitutional symptomse
| 5.9 | 3.2 | 14.8 | 12.5 |
Othere
| 31.2 | 30.9 | 42.7 | 45.2 |
WHO grades 3 and 4 (%) | ||||
Anemiaf
| 3.8 | 6.4 | 5.1 | 7.0 |
Leukocytopenia | 1.6 | 3.1 | 5.2 | 5.5 |
Thrombocytopenia | 3.9 | 4.2 | 7.7 | 8.2 |
Myalgia/arthralgiae
| 2.8 | 1.1 | 2.5 | 1.4 |
Dermatologic AEse
| 0.4 | 5.4 | 2.8 | 2.8 |
Edemae
| 1.2 | 0 | 1.4 | 5.6 |
Gastrointestinal AEse
| 2.0 | 1.1 | 3.2 | 4.8 |
Neurological AEse
| 2.0 | 0 | 2.5 | 4.2 |
Infectione
| 0.8 | 0 | 2.5 | 8.3 |
Fatiguee
| 0.4 | 0 | 2.5 | 1.4 |
Allergy/immunologye
| 0 | 1.1 | 0.4 | 0 |
Constitutional symptomse
| 0.4 | 0 | 0.7 | 0 |
Othere
| 6.3 | 9.6 | 11.6 | 12.5 |
IM400 | IM800 | |||
---|---|---|---|---|
Age (years), (n) | <65 (272) | ≥65 (110) | <65 (319) | ≥65 (83) |
Total deaths (n) | 23 | 21 | 19 | 6 |
Causes (n) | ||||
Progression to AP/BC | 8 | 4 | 9 | 1 |
Transplantation related | 3 | 0 | 4 | 0 |
Infection in CP | 2 | 0 | 2 | 1 |
Secondary malignancy | 1 | 8 | 1 | 2 |
Bleeding | 1 | 0 | 1 | 0 |
Cardiopulmonary | 2 | 2 | 1 | 1 |
Renal insufficiency | 0 | 2 | 0 | 1 |
Thromboembolic/ischemic (not cardiac) | 0 | 1 | 1 | 0 |
Suicide | 0 | 1 | 0 | 0 |
Others | 3 | 0 | 0 | 0 |
Unknown | 3 | 3 | 0 | 0 |